© The Author(s). 2024 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Picroliv, a standardized extract derived from
Wound healing is a complex, multi-phase process involving hemostasis, inflammation, proliferation, and remodeling. The integrity of this process is crucial for restoring skin function and preventing infections. Natural compounds have been explored for their potential to enhance wound healing, with Picroliv emerging as a notable candidate due to its diverse pharmacological properties.
Wound healing, a multifaceted process involving hemostasis, inflammation, proliferation, and remodeling, is crucial for tissue integrity and function. In clinical settings, impaired healing due to oxidative stress and inflammation remains a major challenge. The search for effective wound-healing agents has led researchers to explore natural compounds. One such promising agent is Picroliv, an extract from
Picroliv is a mixture of iridoid glycosides, primarily picroside I and kutkoside, extracted from the roots and rhizomes of
Picroliv is a light yellowish-brown amorphous powder with a bitter taste, containing a 60% mix of picroside I and kutkoside in a 1:1.5 ratio, with the remaining 40% comprising other iridoid and unidentified glycosides (
Oxidative stress, characterized by excessive reactive oxygen species (ROS), impairs wound healing by damaging cellular components. Picroliv has demonstrated significant antioxidant activity, reducing lipid peroxidation and enhancing glutathione (GSH) levels in hepatic tissues (
Wound healing involves a cascade of biochemical and cellular events, including modulation of oxidative stress, regulation of transcription factors, cytokine production, and remodeling. Picroliv’s biological effects span these domains.
Oxidative stress impairs wound healing by damaging cellular proteins, lipids, and DNA. Picroliv exhibits potent antioxidant properties. In H/R models, Picroliv significantly reduced malondialdehyde (MDA), a marker of lipid peroxidation, indicating reduced oxidative injury (
Additionally, Picroliv modulates GSH metabolism. Though GSH levels in the liver dropped after H/R injury, Picroliv improved glutathione reductase (GR) activity significantly, suggesting enhanced recycling of GSH and better redox control (
Picroliv significantly suppresses inflammatory markers by downregulating transcription factors like AP-1 and associated immediate early genes (IEGs) such as c-fos and c-jun. These are crucial mediators of inflammatory gene expression following tissue damage (
Excess nitric oxide (NO), especially when catalyzed by inducible nitric oxide synthase (iNOS), contributes to tissue damage. Picroliv pretreatment markedly decreased iNOS gene expression and nitrite accumulation in liver tissues post-H/R injury (
Inflammation is a critical phase in wound healing, but prolonged inflammation can hinder the process. Picroliv has been shown to downregulate pro-inflammatory cytokines and transcription factors such as NF-κB and AP-1, thereby modulating the inflammatory response (
Angiogenesis, the formation of new blood vessels, is essential for supplying nutrients and oxygen to the healing tissue. Studies have indicated that Picroliv enhances angiogenic activity, as evidenced by increased vascular endothelial growth factor (VEGF) expression and improved neovascularization in wound models (
Effective wound healing requires the proliferation and migration of keratinocytes and fibroblasts. Picroliv has been observed to stimulate these cellular activities, leading to accelerated re-epithelialization and granulation tissue formation (
Comparative analyses have placed Picroliv alongside other phytochemicals like curcumin and ellagic acid in terms of hepatoprotective and antioxidant efficacy (
The multifaceted actions of Picroliv position it as a promising agent in wound management. However, clinical trials are necessary to validate its efficacy and safety in human subjects. Future research should focus on dosage optimization, delivery mechanisms, and long-term outcomes (
Key mechanisms of Picroliv in wound healing.
| Mechanism | Description | Supporting evidence |
| Scavenges reactive oxygen species (ROS) and inhibits lipid peroxidation, protecting tissues from oxidative damage. | Picroliv and its components, picroside-I and kutkoside, have been shown to suppress superoxide anion generation and inhibit malondialdehyde (MDA) formation in liver microsomes, indicating strong antioxidant properties. | |
| Modulates inflammatory responses by downregulating pro-inflammatory cytokines and transcription factors. | Picroliv treatment resulted in decreased activation of NF-κB and AP-1 transcription factors, leading to reduced inflammation in hemorrhaged rats. | |
| Enhances the formation of new blood vessels, crucial for supplying nutrients and oxygen to healing tissues. | In rat models, Picroliv increased vascular endothelial growth factor (VEGF) expression, leading to improved neovascularization and microvessel density in granulation tissue. | |
| Stimulates the proliferation and migration of fibroblasts and endothelial cells, facilitating tissue regeneration. | Picroliv treatment led to enhanced sprouting and migration of endothelial cells in ex vivo rat aorta ring models, indicating its role in promoting cellular proliferation during wound healing. | |
| Accelerates the restoration of the epithelial layer over wounds, leading to faster wound closure. | Histological analyses showed improved re-epithelialization in Picroliv-treated wounds compared to controls, with complete healing observed by day 7. |
A landmark study by Seth et al. (
These multifaceted effects suggest Picroliv as a potent modulator of the wound microenvironment (
Antioxidant activity comparison.
| A table comparing the antioxidant efficacy of Picroliv and its components against standard antioxidants: |
||
| DPPH radical scavenging assay | 1.04 | |
| DPPH radical scavenging assay | 1.04 | |
| DPPH radical scavenging assay | 1.04 | |
| DPPH radical scavenging assay | 0.81 | |
| DPPH radical scavenging assay | 1.04 | |
Note: Lower IC50 values indicate higher antioxidant activity.
The benefits of Picroliv can be contextualized across wound healing stages:
During early healing, oxidative stress and inflammation are prominent. Picroliv mitigates both by enhancing antioxidant enzyme systems (GR, GPx) and inhibiting inflammatory transcription factors (AP-1). This facilitates a cleaner transition from inflammation to tissue proliferation (
Summary of Picroliv’s effects on wound healing parameters.
| A table summarizing the observed effects of Picroliv on various wound healing parameters: |
|
| Parameter | Observed effect with Picroliv treatment |
| Reduced inflammatory markers | |
| Enhanced VEGF expression and neovascularization | |
| Increased proliferation and migration | |
| Accelerated epithelial layer restoration | |
| Complete healing by day 7 | |
While not directly examined in the discussed study, by suppressing stress signals and stabilizing redox balance, Picroliv likely supports fibroblast proliferation and angiogenesis. AP-1 and NO are involved in regulating VEGF and endothelial function; their modulation by Picroliv could enhance neovascularization—a critical step in granulation tissue formation.
Reduced inflammation and oxidative injury foster better collagen deposition and matrix reorganization, essential for wound strength and function restoration.
The oral administration of Picroliv (12 mg/kg body weight) over 7 days showed no toxic effects in rats. Its preparation adheres to WHO guidelines for herbal medicines (
While Picroliv’s hepatoprotective and antioxidant roles are well-documented, direct studies on cutaneous or musculoskeletal wound healing are limited. Future research should:
Investigate Picroliv in cutaneous wound models (e.g., full-thickness excision).
Explore gene and protein markers of angiogenesis and epithelialization (e.g., VEGF, EGF).
Conduct clinical trials in post-surgical or diabetic wound settings.
Assess potential synergies with known wound agents like curcumin or silymarin.
Picroliv, a natural glycoside extract from
cytoprotective effects that are highly relevant to wound healing. Through redox modulation, suppression of pro-inflammatory transcription factors, and regulation of NO synthesis, Picroliv enhances tissue resilience and may significantly promote healing in oxidative and inflammatory wound environments. With further validation, it holds promise as a novel adjunct in wound care therapeutics.
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.